Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that the U.S. Food and Drug ...

Clinical stage biopharmaceutical company Nacuity Pharmaceuticals announced that the US FDA has granted Fast Track designation for its NPI-001 (N-acetylcysteine amide) tablets, a proprietary ...

NPI-001 is a proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA) tablets being developed to target oxidative stress associated with diseases such as retinitis pigmentosa.

A team of researchers at the Medical University of South Carolina has discovered that a commonly used drug, N-acetylcysteine ...

Histamine intolerance is a proposed condition in which a person may have difficulty metabolizing histamine in food. Learn ...

Moreover, pretreating Ca9-22 cells with N-acetylcysteine (NAC) rescued WFA-induced selective killing, apoptosis, G2/M arrest, oxidative stress, and DNA damage. We conclude that WFA induced oxidative ...

Only nebulizers can deliver certain COPD drugs, including metaproterenol and acetylcysteine. Many factors go into deciding what type of COPD treatment may be best for you. Current medical ...

Dr Emma Solly University of Adelaide's Dr Emma Solly and Dr Sivabaskari Pasupathy will share in the latest round of funding from The ...